Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial
Lakewood-Amedex Biotherapeutics doses its first Phase 2a patient with Nu-3 Gel for mildly infected diabetic foot ulcers and drug resistance.
Stocks · News reference
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter to Shareholders
To our shareholders,The second quarter of 2026 represented a transformational period in the evolution of Lakewood-Amedex Biotherapeutics. We successfully transitioned to a Nasdaq-listed public company, significantly
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed In Phase 2a Trial Of Nu-3 For Infected Diabetic Foot Ulcers; Topline Data Expected In Q1 2027
Lakewood-Amedex Registers Resale Of Up To 4,512,400 Shares Of Common Stock By Selling Stockholder
LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. 4,512,400 Shares of Common Stock This prospectus relates to the resale from time to time of up to 4,512,400 shares of common stock, par value $0.0001 per share, of Lakewood-Amedex